Trial · NCT07897708
A Study to Learn How Different Amounts of the Study Medicine Called PF-08161842 Are Tolerated and Act in the Body in Healthy and Older Adults
NCT07897708, Phase 1, Not yet recruiting, Pfizer
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study to Learn How Different Amounts of the Study Medicine Called PF-08161842 Are Tolerated and Act in the Body in Healthy and Older Adults. Trials, record NCT07897708. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07897708
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Learn How Different Amounts of the Study Medicine Called PF-08161842 Are Tolerated and Act in the Body in Healthy and Older Adults
- NCT number
- NCT07897708
- Status
- Not yet recruiting
- Phases
- Phase 1
- Enrollment
- 98 participants, estimated
- Lead sponsor
- Pfizer
- Conditions
- Alzheimer Disease
- Interventions
- PF-08161842, Placebo for PF-08161842
- First posted
- 2026-10-27
- Last updated
- 2026-10-30
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | From first dose through approximately 28 to 35 days after the last dose | |
| Primary | Number of Participants With Serious Adverse Events (SAEs) | From first dose through approximately 28 to 35 days after the last dose | |
| Primary | Number of Participants With Clinically Significant Laboratory Abnormalities | From first dose through approximately 28 to 35 days after the last dose | |
| Primary | Number of Participants With Clinically Significant Vital Signs Abnormalities | From first dose through approximately 28 to 35 days after the last dose | |
| Primary | Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings | From first dose through approximately 28 to 35 days after the last dose | |
| Primary | Number of Participants With Clinically Significant Columbia-Suicidality Severity Rating Scale (C-SSRS) | From first dose through approximately 28 to 35 days after the last dose | |
| Secondary | Area Under the Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) | Part A only: Up to Day 5 | |
| Secondary | Area Under the Curve From Time Zero to end of Dosing Interval (AUCtau) | Part B only: Up to Day 17 | |
| Secondary | Maximum Observed Plasma Concentration (Cmax) | Part A: Up to Day 5 Part B: Up to Day 17 | |
| Secondary | Time to Reach Maximum Observed Plasma Concentration (Tmax) | Part A: Up to Day 5 Part B: Up to Day 17 |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07897708
GET https://conductscience.org/api/trials/v1/NCT07897708/registered